You are here

PG324

Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension

FierceBiotech

Mon, 02/3/14 - 08:19 am

ocular hypertension